Denosumab Effect on Bone Mineral Density and Urinary-NTX in Breast Cancer Patients Receiving Aromatase Inhibitors

Overview

Journal J Bone Miner Metab

Specialty Endocrinology

Date 2023 May 29

PMID 37247110

Authors

Masahiro Shibata

Mai Okumura

Shin Kawano

Hirotoshi Noda

Chihiro Toyota

Yutaka Mizuno

Affiliations

Soon will be listed here.

Abstract

Introduction: Aromatase inhibitors are used post-surgical intervention in postmenopausal patients with breast cancer. However, these drugs accelerate decline in bone mineral density (BMD), which is countered by use of denosumab, and the efficacy of the drug can be assessed by bone turnover markers. We investigated the effects of denosumab administration for 2 years on BMD and urinary N-telopeptide of type I collagen (u-NTX) levels in breast cancer patients treated with aromatase inhibitors.

Materials And Methods: This was a single-center retrospective study. Postoperative hormone receptor-positive breast cancer patients with low T-scores biannually received denosumab from the time of initiation of aromatase inhibitor therapy for 2 years. BMD was measured every 6 months, and u-NTX levels were assessed after 1 month and thereby every 3 months.

Results: The median patient age of the 55 patients included in this study was 69 (range: 51-90) years. BMD gradually increased in the lumbar spine and femoral neck and u-NTX levels were lowest at 3 months post-initiation of therapy. Patients were divided into two groups based on the change ratio of u-NTX 3 months post-denosumab administration. Of these, the group with higher change ratio showed a higher degree of BMD restoration in the lumbar spine and femoral neck 6 months post-denosumab treatment.

Conclusion: Denosumab increased BMD in patients treated with aromatase inhibitors. The u-NTX level decreased soon after start of denosumab treatment, and its change ratio is predictive of improvement in BMD.

References

Ciuba A, Wnuk K, Nitsch-Osuch A, Kulpa M . Health Care Accessibility and Breast Cancer Mortality in Europe. Int J Environ Res Public Health. 2022; 19(20). PMC: 9602737. DOI: 10.3390/ijerph192013605. View

Regan M, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B, Mauriac L . Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up. Lancet Oncol. 2011; 12(12):1101-8. PMC: 3235950. DOI: 10.1016/S1470-2045(11)70270-4. View

Eastell R, Hannon R, Cuzick J, Dowsett M, Clack G, Adams J . Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res. 2006; 21(8):1215-23. DOI: 10.1359/jbmr.060508. View

Qaseem A, Forciea M, Denberg T, Barry M, Cooke M, Fitterman N . Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians. Ann Intern Med. 2017; 166(11):818-839. DOI: 10.7326/M15-1361. View

Papapoulos S, Chapurlat R, Libanati C, Brandi M, Brown J, Czerwinski E . Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res. 2011; 27(3):694-701. PMC: 3415620. DOI: 10.1002/jbmr.1479. View

Gnant M, Pfeiler G, Dubsky P, Hubalek M, Greil R, Jakesz R . Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2015; 386(9992):433-43. DOI: 10.1016/S0140-6736(15)60995-3. View

Ouchi Y, Nakatsukasa K, Sakaguchi K, Morita M, Koyama H, Matsuda T . The effect of denosumab in breast cancer patients receiving adjuvant aromatase inhibitors: 36-month results. J Bone Miner Metab. 2020; 39(2):224-229. DOI: 10.1007/s00774-020-01138-6. View

Kim S, Park D, Park K, Kim S, Cho B, Lee H . Early changes in biochemical markers of bone turnover predict bone mineral density response to antiresorptive therapy in Korean postmenopausal women with osteoporosis. Endocr J. 2006; 52(6):667-74. DOI: 10.1507/endocrj.52.667. View

Eastell R, Christiansen C, Grauer A, Kutilek S, Libanati C, McClung M . Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. J Bone Miner Res. 2010; 26(3):530-7. DOI: 10.1002/jbmr.251. View

10.

Shizuku M, Shibata M, Okumura M, Takeuchi D, Kikumori T, Mizuno Y . Utility of urinary type I collagen cross-linked N-telopeptide as a prognostic indicator in breast cancer patients with bone metastases. Breast Cancer. 2020; 27(6):1065-1071. DOI: 10.1007/s12282-020-01109-9. View

11.

Regan M, Fleming G, Walley B, Francis P, Pagani O . Adjuvant Systemic Treatment of Premenopausal Women With Hormone Receptor-Positive Early Breast Cancer: Lights and Shadows. J Clin Oncol. 2019; 37(11):862-866. PMC: 6455715. DOI: 10.1200/JCO.18.02433. View

12.

Eastell R, Adams J, Coleman R, Howell A, Hannon R, Cuzick J . Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol. 2008; 26(7):1051-7. DOI: 10.1200/JCO.2007.11.0726. View

13.

Coleman R, de Boer R, Eidtmann H, Llombart A, Davidson N, Neven P . Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol. 2012; 24(2):398-405. DOI: 10.1093/annonc/mds277. View

14.

Gnant M, Pfeiler G, Steger G, Egle D, Greil R, Fitzal F . Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019; 20(3):339-351. DOI: 10.1016/S1470-2045(18)30862-3. View

15.

Bone H, Bolognese M, Yuen C, Kendler D, Miller P, Yang Y . Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab. 2011; 96(4):972-80. DOI: 10.1210/jc.2010-1502. View

16.

Nakatsukasa K, Koyama H, Ouchi Y, Sakaguchi K, Fujita Y, Matsuda T . Effect of denosumab administration on low bone mineral density (T-score -1.0 to -2.5) in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer. J Bone Miner Metab. 2017; 36(6):716-722. DOI: 10.1007/s00774-017-0884-x. View

17.

Generali D, Berruti A, Tampellini M, Dovio A, Tedoldi S, Bonardi S . The circadian rhythm of biochemical markers of bone resorption is normally synchronized in breast cancer patients with bone lytic metastases independently of tumor load. Bone. 2006; 40(1):182-8. DOI: 10.1016/j.bone.2006.06.023. View

18.

Coleman R, Brown J, Terpos E, Lipton A, Smith M, Cook R . Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions. Cancer Treat Rev. 2008; 34(7):629-39. PMC: 3090688. DOI: 10.1016/j.ctrv.2008.05.001. View

19.

McCaig F, Renshaw L, Williams L, Young O, Murray J, Macaskill E . A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer. Breast Cancer Res Treat. 2009; 119(3):643-51. DOI: 10.1007/s10549-009-0646-0. View

20.

Lipton A, Smith M, Fizazi K, Stopeck A, Henry D, Brown J . Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive Agents. Clin Cancer Res. 2016; 22(23):5713-5721. DOI: 10.1158/1078-0432.CCR-15-3086. View